HC Wainwright Estimates Rezolute's Q1 Earnings (NASDAQ:RZLT)

Key Points

• HC Wainwright lowered its Q1 2027 EPS estimate for Rezolute to a loss of $0.16 from $0.12, while projecting a $0.57-per-share loss for fiscal 2027 and continued losses through fiscal 2029.
• Despite near-term losses, HC Wainwright maintained a Buy rating and $10 price target; analysts overall assign Rezolute a “Moderate Buy” consensus rating with an average target of $10.
• Rezolute reported quarterly EPS of ($0.20), missing the consensus estimate of ($0.15), while institutional investors own approximately 82.97% of the company’s shares.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Equities researchers at HC Wainwright lowered their Q1 2027 earnings estimates for shares of Rezolute in a report issued on Friday, September 25th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.16) per share for the quarter, down from their prior forecast of ($0.12). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Rezolute's current full-year earnings is ($0.52) per share. HC Wainwright also issued estimates for Rezolute's Q2 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.57) EPS, Q1 2028 earnings at ($0.13) EPS, Q2 2028 earnings at ($0.12) EPS, Q3 2028 earnings at ($0.10) EPS, Q4 2028 earnings at $0.01 EPS, FY2028 earnings at ($0.34) EPS, FY2029 earnings at ($0.14) EPS, FY2030 earnings at $1.42 EPS and FY2031 earnings at $2.94 EPS.

Several other equities research analysts also recently weighed in on RZLT. Citizens Jmp upgraded Rezolute from a "market perform" rating to an "outperform" rating and set a $11.00 price target on the stock in a report on Wednesday, June 3rd. Cantor Fitzgerald restated a "neutral" rating on shares of Rezolute in a research note on Wednesday, June 3rd. Citigroup reaffirmed a "market outperform" rating on shares of Rezolute in a report on Friday. BTIG Research lifted their price target on shares of Rezolute from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Tuesday, June 2nd. Finally, Wedbush boosted their price target on shares of Rezolute from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Wednesday, June 3rd. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $10.00.

Rezolute Trading Up 7.2%

Shares of NASDAQ RZLT opened at $4.18 on Tuesday. The stock has a market cap of $404.29 million, a P/E ratio of -5.50 and a beta of 0.60. The business's fifty day simple moving average is $4.57 and its 200-day simple moving average is $4.03. Rezolute has a 12-month low of $1.07 and a 12-month high of $11.46.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings results on Thursday, September 24th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05).

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Jennison Associates LLC purchased a new stake in shares of Rezolute during the first quarter worth approximately $10,489,000. Siren L.L.C. purchased a new position in Rezolute in the 1st quarter valued at $10,151,000. Dimensional Fund Advisors LP increased its stake in Rezolute by 273.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company's stock valued at $1,617,000 after buying an additional 388,346 shares during the period. Bank of New York Mellon Corp purchased a new position in Rezolute during the 2nd quarter worth $1,104,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Rezolute during the 4th quarter worth $494,000. Hedge funds and other institutional investors own 82.97% of the company's stock.

Rezolute News Roundup

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: HC Wainwright projects Rezolute could reach positive earnings of $1.42 per share in fiscal 2030 and $2.94 per share in fiscal 2031, substantially improving the company’s long-term earnings potential.
• Positive Sentiment: The firm raised its fiscal 2029 EPS forecast to a loss of $0.14 from a loss of $0.17, while maintaining its Buy rating and $10 price target—well above recent trading levels.
• Neutral Sentiment: HC Wainwright expects Rezolute to remain unprofitable through fiscal 2029, with estimates of a $0.57-per-share loss in fiscal 2027, a $0.34 loss in fiscal 2028, and a $0.14 loss in fiscal 2029. The analyst forecasts a return to positive quarterly earnings in the fourth quarter of 2028.
• Negative Sentiment: The analyst lowered its fiscal 2027 EPS forecast to a $0.57 loss from $0.45, cut fiscal 2028 to a $0.34 loss from $0.33, and reduced estimates for the first two quarters of fiscal 2027 and the fourth quarter of fiscal 2027. These revisions point to higher expected near-term losses and may limit the stock’s upside until Rezolute’s pipeline generates revenue.

About Rezolute

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company's research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute's leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.